In this video, Dr. William Chey, Chief of Gastroenterology and Hepatology at the University of Michigan, discusses the latest American College of Gastroenterology (ACG) clinical practice guidelines for the management of H. pylori infection. Speaking at the Allied GI Conference, Dr. Chey highlights why H. pylori remains a significant health concern in the U.S., affecting about one in three individuals and contributing to conditions like peptic ulcer disease and gastric cancer. He outlines key indications for H. pylori testing and treatment, including dyspepsia, unexplained iron deficiency anemia, and family exposure. Dr. Chey also addresses the growing issue of antibiotic resistance—particularly to clarithromycin and levofloxacin—and explains why certain empirical therapies are no longer recommended. He reviews first-line treatment regimens such as bismuth quadruple therapy, rifabutin triple therapy, and vonoprazan-based dual therapy, emphasizing the importance of confirming eradication after treatment. For clinicians seeking a practical, evidence-based approach to diagnosing, treating, and retesting for H. pylori infection, this presentation provides essential updates and expert guidance.
